
Corporate venture arm of Northwestern Mutual investing in financial, health and analytics technology, plus a Wisconsin startup fund

Healthcare venture growth investor in biotechnology, medical technology and health solutions companies

Healthcare investing runs on long timelines, clinical risk and exits that depend on regulators, and Longitude Capital builds its approach around that reality. The firm puts venture growth capital into biotechnology, medical technology and health solutions companies whose work aims to improve clinical outcomes, patient quality of life or the cost of care.
Longitude invests in both privately held and publicly traded companies. Its strategy, as it describes it, is to hold a balanced mix of clinical-stage and commercial-stage businesses whose assets have already been partly de-risked clinically, bought at valuations that look favorable relative to the risk, with returns expected within three to five years of the first investment. The firm has been investing since 2006 and says it has raised capital across six funds, and has shown it can find, manage and exit investments across several market cycles.
Rather than relying on one type of deal, the firm lists a range of structures, running from conventional venture deals and asset spin-outs to recapitalizations, private placements in public companies, market purchases and royalty arrangements, along with other equity-linked instruments. That flexibility lets it fit a company's circumstances, whether it needs a conventional round, a financing tied to a particular asset, or a deal that restructures an existing balance sheet.
New opportunities come from the firm's network of industry relationships and from its own thematic research into emerging therapeutic areas and sub-sectors. After investing, it works with portfolio companies and syndicate partners on strategic plans, operating objectives, hiring, raising capital and routes to liquidity.
The company name refers to the Longitude Prize, a competition set up by the British monarchy in 1714 to solve a major scientific problem of its day. The firm's founders have invested together since 2002, and it says the team has over two hundred years of combined life sciences investing experience and has worked on more than ninety new investments and one hundred and fifty follow-on investments.
It operates from offices in Menlo Park, California and Boston, Massachusetts. Partners are organized by focus, with some concentrating on medical technology and health solutions and others on biotechnology, including royalty transactions.
Longitude Capital is an investment firm specialising in healthcare. It makes venture growth investments in biotechnology, medical technology and health solutions companies, both private and publicly traded, that aim to improve clinical outcomes or reduce the cost of care.
Summary written by TrustList from the business's own published information, Oct 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Longitude Capital.
Similar listings buyers compare against this one.

Corporate venture arm of Northwestern Mutual investing in financial, health and analytics technology, plus a Wisconsin startup fund

Venture capital firm investing in early to growth-stage fintech companies through a network of banks

Investment arm of Liberty Global holding stakes in technology, media, infrastructure and services companies

Seed and early-stage venture capital fund for life sciences companies in Greater Manchester and Cheshire

Bay Capital is an independent India-focused equity investment manager for institutions and families

A multi-fund venture investor combining business, technology and security expertise to back deep-technology start-ups

An investment firm operating private equity, structured capital and credit strategies

US law firm advising start-ups, venture capital and growth equity funds and technology companies
Everything here links back to the same verified catalogue. Pick your next stop.